Introduction {#Sec1}
============

Coronaviruses (CoV), named after its crown-like appearance under electron microscope, were known to cause severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) diseases with high mortality rate \[[@CR1]\]. On March 11, 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) outbreak as pandemic caused by another member of the Coronaviridae family---SARS-CoV-2.

SARS-CoV-2 primarily infects cells of the small air sacs known as alveoli consisting of alveolar cells and alveolar macrophages. There are two types of alveolar cells (type I and II) which are also known as pneumocytes. Type I cells provide 95% of the surface area of each alveoli and are flat hence are named squamous epithelial cells. Type II cells generally cluster in the corners of the alveoli and have a cuboidal shape. Infection by the SARS-CoV-2 causes an inflammatory condition also known as pneumonia affecting primarily alveoli \[[@CR2]\]. Typically, symptoms include a combination of non-productive or dry cough, chest pain, fever, and difficulty in breathing. The pneumonic condition in COVID-19 is severe and is associated with its high mortality \[[@CR3], [@CR4]\].

The current COVID-19 pandemic caused by SARS-CoV-2 has prompted policy makers to take actions to prevent further spread of the virus. The same crisis also made investigators worldwide to search for an effective anti-viral treatment. The current review paper will highlight the potential of Zn supplement with the ongoing treatment modalities for COVID-19 patients. To start with, the paper will first briefly describe the virus and its mechanism of replication in the host cells (generally that is the pneumocytes of the lungs). A brief description will be added to highlight the changes in the host immune responses upon SARS-CoV-2 infection. Subsequently, a summary of the ongoing and recommended treatments will be presented. Finally, the paper will highlight how Zn can contribute to fight the battle with the SARS-CoV-2.

The SARS-COV-2 Virus and Its Replication in Host Pneumocytes (Cells of the Lungs) {#Sec2}
=================================================================================

SARS-CoV-2 is one of the seven types of coronavirus that are known to infect humans \[[@CR4]\]. Based on the genetic properties, coronaviruses are grouped into four genera: α-CoV, β-CoV, γ-CoV, and δ-CoV \[[@CR2]\], and the COVID-19 belongs to β-CoV \[[@CR4]\]. Like other coronaviruses, SARS-CoV-2 is also an enveloped virus with a single-strand, positive-sense RNA genome \[[@CR5]\].

At the beginning of the replicative cycle, the polycistronic viral genome uses a unique transcription mechanism to generate a nested set of subgenomic (sg) mRNAs after entry and uncoating inside the host cell. Using the 5′-proximal open reading frames (ORFs) of the genome, namely ORF1a and ORF1b, two large replicase polyproteins (pp1a and pp1ab) are translated. Eventually, 16 non-structural proteins (NSP) producing mature replicase proteins are released from pp1a and pp1ab attributed to the proteolytic cleavages by ORF1a-encoded proteases. The replicase proteins have a variety of functions that are required for viral RNA synthesis and capping, such as the RNA-dependent RNA polymerase (RdRp; NSP12), a helicase (NSP13), RNA cap-modifying methyltransferases (NSP14 and NSP16), and an exoribonuclease (NSP14). Using the host proteins, the coronavirus NSPs form membrane-associated replication and transcription complexes for viral membrane structures. For detail of the functions of each protein, please see the review by Cheng et al. \[[@CR6]\].

Along with 16 non-structural proteins (NSPs) and four major structural proteins, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N), SARS-CoV-2 contains eight accessory proteins \[[@CR7]\]. The spike proteins have an S1 domain which is responsible for receptor binding and an S2 domain responsible for cell membrane fusion. In other words, S glycoproteins aid binding of the virus to the host cells. The receptor binding domain (RBD) of β-CoV is commonly located in the C-terminal domain of S1 \[[@CR8]\]. The SARS-CoV-2 spike proteins were found to have 10- to 20-fold higher binding affinity to human angiotensin-converting enzyme 2 (ACE2) receptors than SARS-CoV does \[[@CR9]\].

Using spike glycoproteins (S-glycoproteins), the SARS-CoV2 binds to human angiotensin-converting enzyme 2 (ACE2) receptors expressed on pneumocytes \[[@CR10]\]. Notably, ACE2 receptors are widely expressed on the epithelial cells of alveoli, trachea, bronchi, bronchial serous glands \[[@CR11]\], and alveolar monocytes and macrophages \[[@CR12]\].

Binding to ACE2 receptors triggers conformational changes in the S-glycoprotein allowing cleavage by the transmembrane protease-serine 2 of the S-glycoprotein. The virus is then transported into the cytoplasm through a mechanism called endocytosis. The low pH inside the endosomes favours the host protease cathepsin-L to cleave the S-glycoprotein. This results in the fusion of the viral envelope and endosomal phospholipidic membrane to release the positive-strand viral genomic RNA (+RNA) into the cell cytoplasm.

Like other RNA viruses, SARS-CoV-2 genome--encoded RNA-dependent RNA polymerase (RdRp) is central to SARS-CoV-2 replicative cycle. Initially, a polyprotein precursor is formed from which the RdRp-containing subunit is proteolytically cleaved. Subsequently, the RdRp is integrated into a membrane associated viral enzyme complex that drives the synthesis of negative-strand RNA \[[@CR13], [@CR14]\]. The negative RNA strand is used as a template for the synthesis of viral mRNA (Fig. [1](#Fig1){ref-type="fig"}). SARS-CoV-2, MERS-CoV, and SARS-CoV have remarkably similar sequences and encode structurally similar RdRp \[[@CR15]\]. The RdRp has a deep groove as an active site for the polymerization of RNA.Fig. 1Potential sites of action of Zn to counter SARS-CoV-2 in pneumocytes. SARS-CoV uses spike (S) proteins to bind to angiotensin-converting enzyme 2 (ACE2) on pneumocytes (D3). Virus enters the host cell through endocytosis and releases therein the viral RNA (D3). The replicase enzyme complex is translated from the viral genome that mediates both replication and transcription (D4). Virions are shed from the infected cell through exocytosis (E3). The primary site of Zn^2+^ could be the inactivation of the viral replicase (D4). At the same time, the additional Zn supplement might initiate interferon-© (a common anti-viral agent) production by T lymphocytes (B5). However, Zn deprivation in the lysosome of the lymphocytes triggers to secrete perforin, which also exert anti-viral activity (B5). A pool of Zn importing inside the T lymphocytes activates T cell receptors as well as CD25 and CD69 to aid T cell proliferation and stabilization (A2--3). Added Zn also contributes to the production of thymulin from the thymus and triggers T lymphocyte production (A1--2). In alveolar macrophages, Zn can help to degrade the phagocytosed viral particle by the enzymes of the phagolysosome (B-C2). That in turn will help to present the processed An by the major histocompatibility complex (MHC) (B2)

Infected cells contain between 10 and 100 times more +RNA strands than −RNA strands. The polycistronic ribosome machinery of the infected cell synthesizes non-structural proteins of the SARS-CoV-2 and assembles these into the replicase-transcriptase complex to favour viral subgenomic mRNA synthesis. Following replication, the envelope proteins are translated and inserted into the endoplasmic reticulum of the host cells to finally enter into the Golgi compartment. Consequently, the viral genomic RNA is packaged into the nucleocapsid and then envelope proteins are incorporated during the budding step to form mature virions. The M protein plays an essential role during viral assembly by interacting with the other proteins of the virus. Following assembly, the newly formed viral particles are transported to the cell surface in vesicles and are released by exocytosis. A number of detailed reviews have summarized the replication and the assembly of the virus \[[@CR13], [@CR16]\].

Changes in Immune Response in COVID-19 Patients {#Sec3}
===============================================

Immunological profiles of COVID-19 patients seem to vary widely. In general, COVID-19 patients were shown to have normal or lower white blood cell counts, lymphopenia, or thrombocytopenia, with an increased C-reactive protein level \[[@CR3], [@CR8], [@CR17]--[@CR21]\]. In vitro studies of SARS-CoV infection of respiratory epithelial cells, dendritic cells (DCs), showed delayed release of cytokines and chemokines at the early stages. However, higher secretion anti-viral cytokines such as interferons (IFNs) and proinflammatory cytokines such as interleukins (IL) IL-1β, IL-6, and tumour necrosis factor (TNF)) and chemokines (C-C motif chemokine ligand CCL-2, CCL-3, and CCL-5) were recorded in the later stages \[[@CR22]--[@CR24]\].

In a retrospective, single-centre study, involving 99 COVID-19 patients treated in Wuhan Jinyintan Hospital, increased concentrations of C-reactive protein, IL-6, and serum ferritin were recorded along with an increased erythrocyte sedimentation rate \[[@CR19]\]. The same group of patients also showed an increased number of neutrophils with decreased number of lymphocytes. Similar phenomena were observed with cytokine storms, with an overproduction of IL-7, IL-10, GCSF, IP10, MCP1, MIP1A, and TNF-α \[[@CR3], [@CR17]\].

Among the COVID-19 patients (*n* = 69)---admitted to Union Hospital in Wuhan between January 16 and January 29, 2020---only those who had SpO2 \< 90% succumb to the infection \[[@CR25]\]. Compared with the SpO2 ≥ 90% group, patients of the SpO2 \< 90% group were older and showed more comorbidities and higher plasma levels of IL6, IL10, lactate dehydrogenase, and C-reactive protein \[[@CR25]\].

Wang and colleagues \[[@CR26]\] analysed 339 patients with COVID-19 (aged 71 ± 8 years). Among them, 80 (23.6%) were critical, 159 were severe (46.9%), and 100 were moderate (29.5%) cases admitted at the Renmin Hospital of Wuhan University. Compared with the normal values, the count of CD4+ and CD8+ cells was all significantly decreased in these patients. When compared between the survivor (*n* = 274) and non-survivor (*n* = 65) groups, the lymphocyte, monocyte, and platelet counts were significantly decreased in the non-survivor group, but the neutrophil counts were significantly higher. Furthermore, a high level of lymphocytes was found as a predictive better outcome (OR = 0.10, *P* \< 0.001) for the patients who recovered \[[@CR26]\].

Zn Regulation in Human Cells {#Sec4}
============================

Zinc is widely distributed in human tissues, where virtually all Zn is present in intracellular compartments such as the nucleus (30--40%), cytosol, and other organelles and specialized vesicles (50%), and the rest is bound with cell membrane proteins \[[@CR27]\]. While cells need a constant supply of Zn, free Zn ions (Zn^2+^) can be toxic to the cells by inhibiting cytoplasmic enzymes such as adenylate cyclase \[[@CR28]\].

In humans, plasma Zn level is maintained between 10 and 18 mol/L representing 0.1% of total body Zn \[[@CR29]\]. The total zinc content that favours a typical fibroblast-like cell to grow in ordinary culture media is \~ 0.25 fmol per cell or \~ 200 μM. However, in vitro growth of the cells stops at cellular zinc levels below \~ 0.2 fmol per cell \[[@CR30]\].

The intracellular homeostasis of Zn as well as exchange of Zn in and out of the cells is controlled by a large number of proteins belonging to two Zn transporter protein families, SLC39A (Zn importer protein, i.e. ZIP and ZRT/IRT-related protein, 14 ZIP) and SLC30A (Zn Transporter, i.e. ZnT, 10 ZnTs) \[[@CR31]\]. ZnTs generally transport Zn^2+^ out of the cytosol, whereas ZIPs import them from cellular compartments or the extracellular space into the cytosol \[[@CR32], [@CR33]\]. Most ZnTs are present in intracellular compartments, such as endosomes, Golgi, or endoplasmic reticulum while only ZnT1 appears to be located at the plasma membrane as it is the primary regulator of cellular Zn efflux \[[@CR30]\]. Most ZIPs are observed at the plasma membrane; however, Zip7 is located at the Golgi apparatus \[[@CR34]\].

Zinc in Host Immune Mechanisms {#Sec5}
==============================

Unlike other "first row" transition metals/elements, Zn does not participate in redox reactions but rather functions as a Lewis acid to accept a pair of electrons. This property makes Zn^2+^ a stable ion in a biological medium and an ideal metal cofactor for reactions that require a redox-stable ion such as proteolysis and the hydration of carbon dioxide. Metallothioneins---a cysteine-rich low molecular weight group of proteins---act as reservoir of the intracellular concentration of free Zn^2+^ \[[@CR35]--[@CR37]\]. Hence, Zn^2+^ can serve as intracellular second messenger and may trigger apoptosis or a decrease in protein synthesis at elevated concentrations \[[@CR38]--[@CR40]\].

A number of immunome activation pathways are activated by Zn such as NF-κB signalling pathway. NF-κB influences the expression of pro-inflammatory cytokines, namely IL-1b, IL-6, IL-8, TNF-α, and MCP-1, chemokines, acute phase proteins (CRP and fibrinogen), matrix metalloproteinases, adhesion molecules, growth factors, and other factors involved in inflammatory response, such as COX-2 and iNOS \[[@CR41], [@CR42]\].

Zinc administration in mixed lymphocyte cultures was shown to induce and stabilize CD4^+^CD25^+^Foxp3^+^ and CD4^+^CD25^+^CTLA-4^+^ T cells. These effects were attributed to zinc-induced upregulation of Foxp3 and KLF-10 and downregulation of IRF-1 whereas in resting lymphocytes zinc increases IRF-1 \[[@CR43]\]. It is important to note that the number of CD4+ and CD8+ T cells is critical in anti-viral immunity \[[@CR44], [@CR45]\].

On the other hand, Zn depletion can cause a significant suppression of autophagy in cells (human hepatoma cells VL-17A). Conversely, in vitro Zn addition stimulated autophagy in the same cells. Thus, a critical role of Zn was suggested in autophagy under basal conditions \[[@CR46]\]. In various pathological conditions including viral infection, autophagy plays an important protective role as host defence mechanism \[[@CR47]--[@CR49]\]. In autophagy, the intracellular components such as protein aggregates and damaged organelles are engulfed into a double-membrane structure called autophagosome and fuse with lysosome to form autolysosome to degrade the engulfed components using lysosomal enzymes \[[@CR50], [@CR51]\]. Lysosome contains more than 50 enzymes, including proteases, peptidases, phosphatases, nucleases, glycosidases, sulfatases, and lipases \[[@CR52]\]. Essentially, the structural and functional integrity of many of these enzymes depends on Zn \[[@CR53]\].

Immune Regulation of Zinc in Viral Infection {#Sec6}
============================================

In vitro studies involving added Zn^2+^ in the presence of its cellular import stimulatory compounds, such as hinokitiol (HK), pyrrolidine dithiocarbamate (PDTC), and pyrithione (PT), were shown to inhibit the replication of various RNA viruses, including influenza virus \[[@CR54]\], respiratory syncytial virus \[[@CR55]\], and several picornaviruses \[[@CR56]--[@CR58]\]. These reports suggested inhibition of intracellular Zn^2+^ in the replicative cycle of these viruses. More particularly, Zn^2+^ was shown to inhibit polyprotein processing in cells infected with human rhinovirus and coxsackievirus B3 \[[@CR58]\].

In addition to SARS-CoV, a number of other viruses, including HIV, HSV, and vaccinia virus, are known to be inhibited by Zn salts. Zn is known to inhibit the viral entry, blocking of polyprotein processing, or inhibition of viral RdRp activity \[[@CR59]--[@CR61]\]. Using *Huh7* cells transfected with in vitro synthesized capped genomic RNA of a g-1 HEV, Kaushik et al. \[[@CR62]\] showed that Zn but not Mg salts, namely Zn-sulfate and Zn-acetate, can inhibit viral sense and antisense RNA levels by approximately 50% at a working concentration of 10 μM. Thus, Zn salts were shown to directly inhibit the activity of viral RdRp thus inhibiting viral replication.

Recommended and Ongoing Treatments for COVID-19 {#Sec7}
===============================================

The suggested treatments for COVID-19 are, but not limited to, the use of (i) convalescent plasma for COVID-19 treatment \[[@CR63]--[@CR65]\]; (ii) ribavirin, a nucleoside analogue in combination with recombinant interferon showed inhibition of MERS-CoV replication \[[@CR66]\]; (iii) lopinavir/ritonavir---a combination of a protease inhibitor and a booster used for the treatment of human immunodeficiency virus infection \[[@CR67]\]; (iv) remdesivir, a nucleotide analogue that inhibit RNA polymerase with a broad spectrum of anti-viral activities; in inhibition of human and zoonotic coronavirus \[[@CR15], [@CR68], [@CR69]\]; (v) favipiravir (also known as T-705, Avigan or favilavir) is a pyrazinecarboxamide derivative known to inhibit RNA polymerase \[[@CR70]\]. In addition, azithromycin and doxycycline---commonly used antibiotics to inhibit viral replication and IL-6 production \[[@CR71]\] and drugs that suppress IL-1 or IL-1R \[[@CR72]\]---were also suggested for the treatment and prevention of COVID-19 disease.

As of April 21, 2020, more than 500 clinical trials have been registered at the various international and national clinical trial registry sites \[[@CR73]\]. The efficacy of a number of recommended anti-viral drugs has been investigated with various outcomes. Such randomized clinical trials on lopinavir-ritonavir did not show any benefit beyond standard care \[[@CR74]\]; favipiravir, compared with Arbidol, did not significantly improve the clinical recovery rate at day 7 \[[@CR75]\]. Besides, hydroxychloroquine versus hydroxychloroquine combined with azithromycin was investigated following non-randomized trials \[[@CR76]\]. Other ongoing clinical trials include IL-6 inhibitors (tocilizumab and sarilumab), convalescent plasma therapy, stem-cell transfusion, candidate vaccines, and traditional Chinese medicines.

In a systematic review, Cortegiani et al. \[[@CR77]\] argued that "there is sufficient pre-clinical rationale and evidence regarding the effectiveness of chloroquine for treatment of COVID-19 as well as evidence of safety from long-time use in clinical practice for other indications." Chloroquine was shown to inhibit in vitro replication of SARS-CoV-2 in Vero E6 cells in an effective concentration EC~90~ of 6.90 μM that can be easily achieved with standard dosing, due to its favourable penetration into tissues, including in the lung \[[@CR68]\]. This is substantially lower than the concentration detected in human plasma when the drug is prescribed to treat malaria at a dose of 25 mg/kg over 3 days \[[@CR78]\]. However, for COVID-19 patients, a lower dose such as 3.6 mg/kg that are often prescribed to treat rheumatoid arthritis has been suggested for long-term prophylaxis as the dose is similar to IC50 for SARS-CoV \[[@CR78], [@CR79]\]. It is to be noted that hydroxychloroquine showed greater efficacy than chloroquine, at least based on in vitro studies \[[@CR80]\]. Besides, hydroxychloroquine was shown to have minimal risk of toxicity such as retinopathy \[[@CR81]\]. Other recent studies also showed that hydroxychloroquine is a less toxic metabolite of chloroquine, as it is more soluble, and causes less side effects and therefore is safer \[[@CR76], [@CR80], [@CR82], [@CR83]\].

It has been hypothesized that both hydroxychloroquine and chloroquine can interfere with ACE2 receptor glycosylation and prevents SARS-CoV-2 binding to pneumocytes. Chloroquine could also possibly inhibit sialic acid biosynthesis thus limiting cell surface binding of SARS-CoV-2. In case the viral particle is endocytosed, chloroquine has been hypothesized to modulate the acidification of endosomes thereby inhibiting formation of the autophagosome. Through reduction of cellular mitogen-activated protein (MAP) kinase activation, chloroquine may also inhibit virus replication. Moreover, chloroquine could alter M protein maturation and interfere with virion assembly and budding \[[@CR16]\].

It is to be noted that both chloroquine and hydroxychloroquine are weak bases present in protonated form in the extracellular environment hence are incapable of crossing the plasma membrane. In the non-protonated form, chloroquine and hydroxychloroquine may enter the intracellular compartments and gradually become protonated according to the Henderson-Hasselbach law. This conversion allows both chloroquine and hydroxychloroquine to reside in acidic organelles such as the endosome, Golgi vesicles, and the lysosomes. \[[@CR84]\].

Why Is Zn Critical for COVID-19 Treatment? {#Sec8}
==========================================

Zn Can Enhance Cell-Mediated and Adaptive Immunity in the Course of Infection {#Sec9}
-----------------------------------------------------------------------------

Zinc is thoroughly involved in cell-mediated immunity against any infectious agent such as bacteria and virus. Zinc is one of the major factors that control function and proliferation of neutrophils, NK cells, macrophages, and T and B lymphocytes as well as cytokine production by the immune cells. Zn also mediates protection from the adverse effect of ROS that are generally produced during inflammatory processes. Free intracellular Zn^2+^ is essential in extravasation to the site of the infection and uptake and killing of microorganisms by neutrophils \[[@CR85]\]. For more detail on the functions of Zn in immunity, please see the review articles by \[[@CR86]--[@CR89]\].

Augmented Effect of Zn and Chloroquine to Stop SARS-CoV-2 Replication {#Sec10}
---------------------------------------------------------------------

Chloroquine was known to increase vacuolar pH when trapped in acidic organelles, such as lysosomes. This increase in pH disrupts lysosomal acidification leading to the impairment of autophagosome fusion and autophagic degradation \[[@CR90], [@CR91]\]. Using human ovarian carcinoma cell line A2780, Xue J. et al. \[[@CR92]\] reported that chloroquine can act as ionophore for Zn. Chloroquine enhances uptake of Zn by the lysosomes, and the combination of Zn and chloroquine enhances chloroquine cytotoxicity and induces apoptosis in malignant cells. In their experiment \[[@CR92]\], A2780 ovarian cancer cells were treated with 100--300 μM chloroquine in the presence of increased concentrations of ZnCl~2~ for 1 h. Intracellular basal Zn levels were barely detectable in control cells without any chloroquine. However, chloroquine addition to the culture medium caused significant increases of intracellular Zn in a dose-dependent manner.

Zn Can Directly Inhibit SARS-CoV-2 Replication {#Sec11}
----------------------------------------------

Using recombinant SARS-CoV nsp12, te Velthuis et al. \[[@CR61]\] showed that Zn^2+^ directly inhibited the in vitro RdRp activity (Fig. [1](#Fig1){ref-type="fig"}). They also reported that specifically, Zn^2+^ was found to inhibit the SARS-CoV RdRp elongation and template binding. Earlier, it was also shown that Zn^2+^ inhibited the proteolytic processing of replicase polyproteins \[[@CR93], [@CR94]\].

Zn Enhances Efficiency of Anti-viral Drugs {#Sec12}
------------------------------------------

A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, and antibiotics such as azithromycin and doxycycline have been recommended for the treatment of COVID-19. Zn supplement can favour COVID-19 treatment using some of these anti-viral drugs.

Zinc supplementation was suggested as a complementary therapy in chronic hepatitis C patients to increase the tolerance to IFN-α-2a and ribavirin \[[@CR95]\]. However, a 24-week Zn supplementation reduced the incidence of abdominal discomfort without any additive effect on the anti-hepatitis C virus dual therapy of IFN-α-2 and ribavirin \[[@CR96]\].

While evaluating the impact of ZnSO~4~ supplementation in HIV-infected individuals, the supplement was found useful in management of atazanavir-ritonavir-related unconjugated hyperbilirubinemia in selected patients \[[@CR67]\].

Zinc Supplement: Limits and Risks {#Sec13}
=================================

Zinc as an adjuvant therapy can be prescribed in different forms of Zn salt, such as Zn-gluconate, Zn-acetate, Zn-sulfate, and Zn-picolinate. However, the amount of elemental Zn in each salt varies. For example, Zn-sulfate contains about 23% elemental Zn; therefore, to have 50 mg of Zn, a 220 mg of Zn-sulfate tablet would be required for consumption. It is important to note that the recommended daily allowance of Zn will vary according to the age, sex, and health conditions of an individual. For healthy adults, the recommended daily allowance is typically 15--30 mg of elemental Zn. Despite the beneficial effects of Zn in immune response, long-term high-dose Zn consumption will cause a decrease of high-density lipoprotein cholesterol levels, anaemia, copper deficiency, and possible genitourinary complications \[[@CR97]\].

Conclusion {#Sec14}
==========

Zinc plays crucial roles in many aspects of life. In the course of infection, the immunomodulatory role of Zn is well evident. In the current pandemic of SARS-CoV-2, Zn supplement could play an important role to treat COVID-19 patients such as (i) added immune boosting effects with anti-viral drugs and (ii) stopping SARS-CoV-2 replication in infected cells, if combined with chloroquine. In view of this discussion, oral Zn supplement can be given using a suitable form of Zn-salt.
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